Search
-
20 F 2014
Media
https://www.gsk.com/media/8091/20-f-2014.pdf
First published: 01 June 2022
-
20-F 2014
Media
https://www.gsk.com/media/2709/20-f-2014.pdf
First published: 13 June 2017
-
ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV
Media
Data from the BANNER study show antiviral efficacy, safety, and tolerability of N6LS, supporting its continued study in phase IIb
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-proof-of-concept-findings-for-n6ls/
First published: 25 October 2022
-
ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV
Media
Maturation inhibitors are a class of antiretroviral medicines that target the late stage of the HIV viral life cycle.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-proof-of-concept-findings-for-gsk3640254-a-novel-investigational-maturation-inhibitor-for-the-treatment-of-hiv/
First published: 09 March 2021
-
GSK receives marketing authorisation from the European Commission for additional Revolade™
Media
GSK announced that the EC has granted Revolade™ as a treatment for thrombocytopenia in adult patients with chronic hepatitis C infection.
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-marketing-authorisation-from-the-european-commission-for-additional-revolade/
First published: 24 September 2013
-
The UK Government signs influenza pandemic contract with GlaxoSmithKline for Relenza®
Media
The UK is now one of the leading countries in stockpiling antivirals for treating infected individuals in event of an influenza pandemic
https://www.gsk.com/en-gb/media/press-releases/the-uk-government-signs-influenza-pandemic-contract-with-glaxosmithkline-for-relenza/
First published: 28 January 2009
-
GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepatitis C infection
Media
GSK announced a positive opinion from EMA's CHMP recommending marketing authorisation for Revolade™ (eltrombopag).
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-for-revolade-in-thrombocytopenia-associated-with-chronic-hepatitis-c-infection/
First published: 26 July 2013
-
Tony Wood
Company
Tony was appointed Chief Scientific Officer designate on 19 January 2022 and became Chief Scientific Officer on 1 August 2022.
https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/tony-wood/
First published: 01 March 2024
-
Unlocking the power of the immune system to get ahead of hepatitis B
Behind the science magazine
GSK’s innovation team have developed a longer-lasting, more effective treatment for this global health problem
https://www.gsk.com/en-gb/behind-the-science-magazine/unlocking-the-power-of-the-immune-system-to-get-ahead-of-hepatitis-b/
First published: 22 June 2022
-
ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months
Media
ATLAS-2M study met its primary endpoint.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-reports-positive-phase-iii-study-results-of-investigational-long-acting-injectable-hiv-treatment-regimen-administered-every-two-months/
First published: 22 August 2019